228670.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 1.05, indicating a moderate level of leverage. Its liquidity position is supported by cash and equivalents of 28,328,090,940 KRW, but the net cash position is negative after subtracting total debt, signaling potential liquidity constraints. The price-to-book ratio of 1.39 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible asset premium.

Profitability metrics reveal a return on equity (ROE) of 4.1% and a return on assets (ROA) of 1.63%, both of which are below the industry median for the Advanced Medical Equipment & Technology sector. The company's operating income is negative at -21,052,369,630 KRW, which contrasts with a net income of 3,137,937,340 KRW, likely due to non-operating income or gains. Gross profit of 52,753,616,760 KRW represents 47.4% of revenue, which is in line with industry norms.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segmental and geographic detail limits the ability to assess exposure to regional or product-specific risks. The absence of disclosed revenue by segment or region suggests a potential concentration risk.

The company's growth trajectory is mixed. While revenue for the latest period is reported at 111,322,950,250 KRW, the operating loss indicates a challenge in converting revenue into profit. Analysts have provided a mean price target of 10,900 KRW, which is 59.6% above the current market price of 6,810 KRW, suggesting a positive outlook. However, the mean recommendation of 2.50 (on a 1-5 scale) indicates a cautious stance, with no strong buy ratings.

Risk factors include a medium liquidity risk due to the negative net cash position and a debt-to-equity ratio above 1. The dilution risk is assessed as low, with no significant dilution potential in the near term. The company's operating cash flow of 12,849,772,560 KRW and free cash flow of 6,045,071,500 KRW provide some buffer against short-term obligations, but the capital expenditure of -3,621,906,480 KRW suggests ongoing investment in infrastructure or equipment.

Recent events include the publication of the latest financial statements, which show a net income despite a significant operating loss. No recent filings or transcripts have been provided that detail specific strategic initiatives or operational changes. The company's capital structure and profitability metrics suggest a need for operational improvements to sustain long-term growth.